D. E. Shaw & Co., Inc. Prometheus Biosciences, Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $7.48 Million - $9.14 Million	72,338 Added 9.97%	797,567 $85.6 Million
Q4 2022 Feb 14, 2023	BUY	$36.06 - $117.21 $20.3 Million - $66.1 Million	563,848 Added 349.39%	725,229 $79.8 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $3.31 Million - $6.93 Million	117,360 Added 266.6%	161,381 $9.52 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $557,107 - $968,905	-24,882 Reduced 36.11%	44,021 $1.24 Million
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $1.58 Million - $2.62 Million	52,432 Added 318.33%	68,903 $2.6 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $366,973 - $651,263	16,471 New	16,471 $651,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.